Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Teva Pharma (NASDAQ: TEVA) price target of $42.00.
Analyst, Douglas D. Tsao, said, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Douglas D. Tsao, said, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
